Brazier Joan F, Trivedi Amal N, Tyler Denise A, Shield Renee R, Gadbois Emily A
Department of Health Services, Policy & Practice, Brown University School of Public Health, Providence, Rhode Island.
Scripps Gerontology Center, Miami University, Oxford, Ohio.
JAMA Netw Open. 2025 Jun 2;8(6):e2516359. doi: 10.1001/jamanetworkopen.2025.16359.
The 21st Century Cures Act expanded Medicare Advantage (MA) to include persons with kidney failure. Little is known about the impact of increased MA marketing for persons with end-stage kidney disease (ESKD).
To examine varied perspectives on the expansion of MA to include persons with ESKD and associated marketing strategies.
DESIGN, SETTING, AND PARTICIPANTS: This qualitative study of interviews conducted from January 21, 2022, to May 1, 2024, used a modified grounded theory and content analysis approach to analyze transcripts. Interviewees included executives from 8 MA plans, clinical leadership of 5 kidney care management companies, and leadership and staff of 6 dialysis organizations that varied in size (enrollment) from all US Census regions.
One-time, semistructured interviews. Interview questions focused on the perceived effects of the expansion of MA to include persons with kidney failure.
Thematic description of participant perspectives on the expansion of MA and associated marketing practices.
A total of 48 interviews with 56 executives and staff from MA plans, kidney care management companies, and dialysis organizations were completed. Analysis found 3 major themes. First, organizations used various outreach approaches to inform persons with kidney failure of their expanded insurance options. Participants recognized that personal choice without undue influence is paramount when older or chronically ill adults are selecting their insurance coverage. Second, MA has potential benefits for persons with ESKD, and organizations expanded partnerships with brokers and/or agencies to provide additional insurance-related resources. Third, the mass marketing approach used to advertise MA was ubiquitous and often reported as deceptive for older or chronically ill adults. Kidney health care professionals noted that constraints on eligibility, restricted health care networks, and limited benefits and services were frequently inadequate for the complex social and medical needs of their patient population.
In this qualitative study, findings show that MA marketing to increase enrollment is pervasive and intensifies during open enrollment. Policymakers and industry experts should consider the complexity of insurance selection decisions and monitor accuracy of MA marketing of ESKD-specific benefits.
《21世纪治愈法案》将医疗保险优势计划(MA)扩大到包括肾衰竭患者。对于终末期肾病(ESKD)患者而言,MA营销增加所带来的影响鲜为人知。
探讨将MA扩大到包括ESKD患者以及相关营销策略的不同观点。
设计、背景和参与者:这项定性研究通过2022年1月21日至2024年5月1日进行的访谈展开,采用了改良的扎根理论和内容分析方法来分析访谈记录。受访者包括来自8个MA计划的高管、5家肾脏护理管理公司的临床负责人,以及来自美国所有人口普查地区、规模(参保人数)各异的6家透析机构的负责人和工作人员。
一次性半结构化访谈。访谈问题聚焦于MA扩大到包括肾衰竭患者的感知影响。
参与者对MA扩大及相关营销实践的观点的主题描述。
共完成了对来自MA计划、肾脏护理管理公司和透析机构的56名高管和工作人员的48次访谈。分析发现了3个主要主题。首先,各机构采用了各种推广方式,向肾衰竭患者告知其扩大后的保险选择。参与者认识到,在老年人或慢性病成年人选择保险覆盖范围时,不受不当影响的个人选择至关重要。其次,MA对ESKD患者有潜在益处,各机构扩大了与经纪人和/或代理机构的合作,以提供更多与保险相关的资源。第三,用于宣传MA的大规模营销方式无处不在,且经常被报告对老年人或慢性病成年人具有欺骗性。肾脏医疗保健专业人员指出,资格限制、受限的医疗保健网络以及有限的福利和服务,往往无法满足其患者群体复杂的社会和医疗需求。
在这项定性研究中,结果表明为增加参保人数而进行的MA营销很普遍,且在开放注册期间会加剧。政策制定者和行业专家应考虑保险选择决策的复杂性,并监测MA针对ESKD特定福利的营销准确性。